治療抵抗性うつ病(Treatment Resistant Depression):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Treatment Resistant Depression - Pipeline Review, H2 2014
◆商品コード:GMDHC5718IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月18日
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における治療抵抗性うつ病(Treatment Resistant Depression)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・治療抵抗性うつ病(Treatment Resistant Depression)の概要
・治療抵抗性うつ病(Treatment Resistant Depression)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・治療抵抗性うつ病(Treatment Resistant Depression)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・治療抵抗性うつ病(Treatment Resistant Depression)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・治療抵抗性うつ病(Treatment Resistant Depression)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Treatment Resistant Depression – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Treatment Resistant Depression – Pipeline Review, H2 2014’, provides an overview of the Treatment Resistant Depression’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Treatment Resistant Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Treatment Resistant Depression and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Treatment Resistant Depression
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Treatment Resistant Depression and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Treatment Resistant Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Treatment Resistant Depression pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Treatment Resistant Depression
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Treatment Resistant Depression pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Treatment Resistant Depression Overview 6
Therapeutics Development 7
Pipeline Products for Treatment Resistant Depression – Overview 7
Pipeline Products for Treatment Resistant Depression – Comparative Analysis 8
Treatment Resistant Depression – Therapeutics under Development by Companies 9
Treatment Resistant Depression – Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Treatment Resistant Depression – Products under Development by Companies 13
Treatment Resistant Depression – Companies Involved in Therapeutics Development 14
Addex Therapeutics Ltd 14
Avanir Pharmaceuticals, Inc. 15
Cerecor Inc. 16
Edgemont Pharmaceuticals, LLC 17
F. Hoffmann-La Roche Ltd. 18
Johnson & Johnson 19
MarcoPolo Pharmaceuticals SA 20
Treatment Resistant Depression – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 30
(dextromethorphan hydrobromide + quinidine sulfate) – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AVP-786 – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
basimglurant – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
BC-19 – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CERC-301 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
EDG-006 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
esketamine – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
EVT-100 Series – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
EVT-103 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecules to Inhibit mGluR2 for Central Nervous System Disorders – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Treatment Resistant Depression – Recent Pipeline Updates 46
Treatment Resistant Depression – Dormant Projects 53
Treatment Resistant Depression – Discontinued Products 54
Treatment Resistant Depression – Product Development Milestones 55
Featured News & Press Releases 55
Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis 55
Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57

[List of Tables]
Number of Products under Development for Treatment Resistant Depression, H2 2014 7
Number of Products under Development for Treatment Resistant Depression - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Comparative Analysis by Unknown Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Treatment Resistant Depression - Pipeline by Addex Therapeutics Ltd, H2 2014 14
Treatment Resistant Depression - Pipeline by Avanir Pharmaceuticals, Inc., H2 2014 15
Treatment Resistant Depression - Pipeline by Cerecor Inc., H2 2014 16
Treatment Resistant Depression - Pipeline by Edgemont Pharmaceuticals, LLC, H2 2014 17
Treatment Resistant Depression - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 18
Treatment Resistant Depression - Pipeline by Johnson & Johnson, H2 2014 19
Treatment Resistant Depression - Pipeline by MarcoPolo Pharmaceuticals SA, H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Assessment by Combination Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 29
Treatment Resistant Depression Therapeutics - Recent Pipeline Updates, H2 2014 46
Treatment Resistant Depression - Dormant Projects, H2 2014 53
Treatment Resistant Depression - Discontinued Products, H2 2014 54

[List of Figures]
Number of Products under Development for Treatment Resistant Depression, H2 2014 7
Number of Products under Development for Treatment Resistant Depression - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Top 10 Targets, H2 2014 23
Number of Products by Stage and Top 10 Targets, H2 2014 24
Number of Products by Top 10 Mechanism of Actions, H2 2014 25
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 26
Number of Products by Top 10 Routes of Administration, H2 2014 27
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 28
Number of Products by Stage and Top 10 Molecule Types, H2 2014 29

【掲載企業】

Addex Therapeutics Ltd
Avanir Pharmaceuticals, Inc.
Cerecor Inc.
Edgemont Pharmaceuticals, LLC
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
MarcoPolo Pharmaceuticals SA

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[治療抵抗性うつ病(Treatment Resistant Depression):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆